Although midostaurin is a competitive inhibitor of ATP binding to PKCα, midostaurin is most active in inhibiting particulate (active) PKC enzymes from tumour samples (Killion et al, 1995; Ikegami et al, 1996). The gene discussed is PRRT2; the disease is neoplasm.